FDA Approves Capivasertib for Specific Advanced Breast Cancers.

Published Date: 18 Nov 2023

In patients with tumors altered by PIK3CA/AKT1/PTEN, the first-in-class AKT inhibitor given in combination with fulvestrant increased PFS compared to fulvestrant used alone.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Long Wait Times on the Other Side of the Pond: King Charles' Cancer Diagnosis.

2.

recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.

3.

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

4.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

5.

Telehealth in the pandemic era resulted in fewer therapy interruptions.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot